Clinical data | |
---|---|
Trade names | Actonel, Atelvia, Benet, others |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 0.63% |
Protein binding | ~24% |
Metabolism | None |
Elimination half-life | 1.5 h |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.436 |
Chemical and physical data | |
Formula | C7H11NO7P2 |
Molar mass | 283.113 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate.[1] It slows down the cells which break down bone.[1] It's used to treat or prevent osteoporosis, and treat Paget's disease of bone.[1] It is taken by mouth.[1]
It was patented in 1984 and approved for medical use in 1998.[2]